Efficiently Identifying Individuals at High Risk for Treatment Resistance in Major Depressive Disorder Using Electronic Health Records
Overview
Affiliations
Background: With the emergence of evidence-based treatments for treatment-resistant depression, strategies to identify individuals at greater risk for treatment resistance early in the course of illness could have clinical utility. We sought to develop and validate a model to predict treatment resistance in major depressive disorder using coded clinical data from the electronic health record.
Methods: We identified individuals from a large health system with a diagnosis of major depressive disorder receiving an index antidepressant prescription, and used a tree-based machine learning classifier to build a risk stratification model to identify those likely to experience treatment resistance. The resulting model was validated in a second health system.
Results: In the second health system, the extra trees model yielded an AUC of 0.652 (95% CI: 0.623-0.682); with sensitivity constrained at 0.80, specificity was 0.358 (95% CI: 0.300-0.413). Lift in the top quintile was 1.99 (95% CI: 1.76-2.22). Including additional data for the 4 weeks following treatment initiation did not meaningfully improve model performance.
Limitations: The extent to which these models generalize across additional health systems will require further investigation.
Conclusion: Electronic health records facilitated stratification of risk for treatment-resistant depression and demonstrated generalizability to a second health system. Efforts to improve upon such models using additional measures, and to understand their performance in real-world clinical settings, are warranted.
Clinical associations with treatment resistance in depression: An electronic health record study.
Coombes B, Sanchez-Ruiz J, Fennessy B, Pazdernik V, Adekkanattu P, Nunez N Psychiatry Res. 2024; 342():116203.
PMID: 39321638 PMC: 11617277. DOI: 10.1016/j.psychres.2024.116203.
Xu B, Forthman K, Kuplicki R, Ahern J, Loughnan R, Naber F medRxiv. 2024; .
PMID: 39006419 PMC: 11245070. DOI: 10.1101/2024.07.03.24309914.
Kang J, Castro V, Ripperger M, Venkatesh S, Burstein D, Linner R Am J Psychiatry. 2024; 181(7):608-619.
PMID: 38745458 PMC: 11905962. DOI: 10.1176/appi.ajp.20230247.
How Real-World Data Can Facilitate the Development of Precision Medicine Treatment in Psychiatry.
Koch E, Pardinas A, OConnell K, Selvaggi P, Camacho Collados J, Babic A Biol Psychiatry. 2024; 96(7):543-551.
PMID: 38185234 PMC: 11758919. DOI: 10.1016/j.biopsych.2024.01.001.
Vogelgsang J, Dan S, Lally A, Chatigny M, Vempati S, Abston J Alzheimers Dement (Amst). 2023; 15(3):e12464.
PMID: 37745891 PMC: 10517223. DOI: 10.1002/dad2.12464.